Anthem Biosciences (NSE:ANTHEM) Other Current Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANTHEM Anthem Biosciences Ltd NSE:ANTHEM
23 GF Score
Price ₹891.65
! 6 Warning Signs
View Full Analysis

What is Anthem Biosciences Other Current Liabilities?

Anthem Biosciences NSE:ANTHEM +4.53% 23 Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ANTHEM with a GF Score™ of 23/100. The stock has 6 warning signs investors should review.

Anthem Biosciences's other current liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Anthem Biosciences's quarterly other current liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,789 Mil) but then declined from Mar. 2026 (₹1,789 Mil) to Jun. 2026 (₹0 Mil).

Anthem Biosciences's annual other current liabilities increased from Mar. 2024 (₹659 Mil) to Mar. 2025 (₹866 Mil) and increased from Mar. 2025 (₹866 Mil) to Mar. 2026 (₹1,789 Mil).

Anthem Biosciences Other Current Liabilities Related Terms

Anthem Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Anthem Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences Other Current Liabilities Chart

Anthem Biosciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
994.03 300.09 659.21 865.75 1,788.83

Anthem Biosciences Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 2,891.64 0.00 1,788.83 0.00
NSE:ANTHEM
23GF Score
Anthem Biosciences Ltd NSE:ANTHEM
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anthem Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹0 Mil mean?
Anthem Biosciences (NSE:ANTHEM) has a Other Current Liabilities of ₹0 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Anthem Biosciences.
Is Anthem Biosciences' Other Current Liabilities too high?
Anthem Biosciences' current Other Current Liabilities is ₹0 Mil. Overall, Anthem Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Other Current Liabilities compare to VRTX and REGN?
Anthem Biosciences' Other Current Liabilities of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Anthem Biosciences. Anthem Biosciences's current Other Current Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Other Current Liabilities of ₹0 Mil. The current Other Current Liabilities is ₹0 Mil. Anthem Biosciences' overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthem Biosciences Business Description

Other Exchanges 544449:India
Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, KA, IND, 560 099
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
23GF Score

Get the complete analysis for NSE:ANTHEM

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹891.65
Price